Advanced in Plasmacytoma

Dr. Meera Mohan

Hematology Oncology | Hematology | Oncology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Accepting New Patients
Offers Telehealth
Advanced in Plasmacytoma
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Meera Mohan is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Mohan is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Light Chain Deposition Disease (LCDD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mohan is currently accepting new patients.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Plasmacytoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A Phase I, Open-label, Multicenter, Study of WVT078 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: December 24, 2025
Intervention Type: Biological, Drug
Study Drugs: WVT078, WHG626
Study Phase: Phase 1
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Study Phase: Phase 2
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Study Phase: Phase 3
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug, Device
Study Drug: MEL-CFZ-TD-PACE
Study Phase: Phase 2
Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Distinguished in Plasmacytoma
Dr. Binod Dhakal
Hematology Oncology | Hematology | Oncology
Distinguished in Plasmacytoma
Dr. Binod Dhakal
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.1 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Binod Dhakal is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Dhakal is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dhakal is currently accepting new patients.

Advanced in Plasmacytoma
Dr. Amarendra K. Neppalli
Hematology Oncology | Hematology | Oncology
Advanced in Plasmacytoma
Dr. Amarendra K. Neppalli
Hematology Oncology | Hematology | Oncology

Aurora Advanced Healthcare, Inc.

2900 W Oklahoma Ave, 
Milwaukee, WI 
 (5.2 miles away)
414-649-6000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Amarendra Neppalli is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Neppalli is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Neppalli is currently accepting new patients.

Advanced in Plasmacytoma
Dr. Anita B. D'souza
Hematology Oncology | Hematology | Oncology
Advanced in Plasmacytoma
Dr. Anita B. D'souza
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.1 miles away)
414-805-3666
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Anita D'souza is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. D'souza is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. D'souza is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mohan's expertise for a condition
ConditionClose
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile